Drug Information Association Begins Transition to New Executive Leadership
Published: Dec 05, 2012
“Paul has been an extraordinary executive director who will be sorely missed, but together we have built a strong foundation for continued growth,” said DIA President Dr. Ling Su. “We are committed to continuing the implementation of our strategic plan, which is bringing quality programs and services to our members and stakeholders globally. We thank Paul for his contributions and wish him the best of success in his new position.”
Under the leadership of Mr. Pomerantz, DIA has achieved rapid global expansion and significantly increased its stakeholder relationships—particularly among global health organizations, regulatory agencies and patient groups—driving its transformation into a world-class, knowledge-driven organization.
“This was a very difficult decision to make,” Mr. Pomerantz said. “The last three years have been among the most fulfilling of my professional career. I am proud of what we accomplished, and confident that DIA’s Board of Directors, staff and volunteers will continue our progress. My new position provides an exciting challenge to serve the needs of a leading medical association and its patients.”
The DIA Board of Directors will announce plans for the executive director search in January.
DIA is a neutral, global, professional and member-driven association of nearly 18,000 professionals involved in the discovery, development and lifecycle management of pharmaceuticals, biotechnology, medical devices and related health care products. Through our international educational offerings and myriad networking opportunities, DIA provides a global forum for knowledge exchange that fosters the innovation of products, technologies and services to improve health and well-being worldwide. Headquarters are in Horsham, Pa., USA, with offices in Basel, Switzerland; Tokyo, Japan; Mumbai, India; Beijing, China; Washington, D.C.; and Latin America.